Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs-Reference-Cited by-同舟云学术

Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs

Published:2019-01 Issue:1 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Weinstein Zohar B.¹,Zaman Muhammad H.²³

Affiliation:

1. Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts, USA

2. Howard Hughes Medical Institute, Boston University, Boston, Massachusetts, USA

3. Department of Biomedical Engineering, Boston University, Boston, Massachusetts, USA

Abstract

Poor-quality medicines undermine the treatment of infectious diseases, such as tuberculosis, which require months of treatment with rifampin and other drugs. Rifampin resistance is a critical concern for tuberculosis treatment.

Funder

HHS | NIH | National Institute of General Medical Sciences

United States Pharmacopeia

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01243-18

Reference39 articles.

1. Treatment of Tuberculosis

2. New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development

3. Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008–2014

4. Sublethal Antibiotic Treatment Leads to Multidrug Resistance via Radical-Induced Mutagenesis

5. Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcription Attenuation in Synthetic Promoters in Nonoverlapping Tandem Formation;Biochemistry;2024-07-12

2. Access to and utilisation of antimicrobials among forcibly displaced persons in Uganda, Yemen and Colombia: a pilot cross-sectional survey;BMJ Open;2024-07

3. The scope of the antimicrobial resistance challenge;The Lancet;2024-06

4. In Silico Drug Repurposing Endorse Amprenavir, Darunavir and Saquinavir to Target Enzymes of Multidrug Resistant Uropathogenic E. Coli;Indian Journal of Microbiology;2024-04-26

5. Detecting Class 1 Integrons and Their Variable Regions in Escherichia coli Whole-Genome Sequences Reported from Andean Community Countries;Antibiotics;2024-04-25